Bruce Barker, MD
Obesity Medicine · Delaware, OHNPI 1972544013
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $95,694 of the $111,769 with a category attached, or 85.6%. Lilly USA, LLC accounts for 88.3% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $56,942, 6.1 times the $9,278 reported in 2019.
Across 200 payments — averaging $558.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$99K
- Novo Nordisk$10K
- Eli Lilly$3K
- AbbVie$45
- Shield Therapeutics Inc$16
- Pfizer$14
- plus $26 from 2 others
Across 1 payment — averaging $8543.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$9K
What the payments were for
- Consulting fees$6,4756%
- Speaking & faculty fees$95,69486%
- Travel & lodging$6,2736%
- Food & beverage$3,3163%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 160 | $98,689 |
| Novo Nordisk | 30 | $9,563 |
| Eli Lilly | 3 | $3,416 |
| AbbVie | 3 | $45 |
| Shield Therapeutics Inc | 1 | $16 |
| Pfizer | 1 | $14 |
| GSK | 1 | $14 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 323 | $370,831 |
| OzempicSemaglutide | 275 | $277,533 |
| TrulicityDulaglutide | 81 | $97,704 |
| WegovySemaglutide | 46 | $63,177 |
| JardianceEmpagliflozin | 58 | $40,793 |
| LinzessLinaclotide | 25 | $14,357 |
| FarxigaDapagliflozin Propanediol | 21 | $11,988 |
| JanuviaSitagliptin Phosphate | 16 | $8,959 |
| Naltrexone Hcl | 138 | $7,621 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,465 |
| Bupropion XlBupropion Hcl | 271 | $3,901 |
| Lisdexamfetamine Dimesylate | 17 | $2,738 |
| Bupropion Hcl SrBupropion Hcl | 155 | $2,571 |
| Topiramate | 354 | $1,895 |
| Zonisamide | 104 | $1,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $98,689 | $468,534404 claims |
| Novo NordiskOzempic, Wegovy | $9,563 | $340,710321 claims |
| AbbVieLinzess, Synthroid | $45 | $14,96137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few obesity medicine providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other obesity medicine in Delaware
- Winfield ButschCleveland$102K
- Donald CundiffSandusky$76K
- Nina GrayCincinnati$1K
- Natasha KorenAkron$313
- Norma AtkinsonCleveland$295
- Christine WallaceCincinnati$284
- Taylor KantorColumbus$157
- Vivek MathurAkron$147
- Irene DejakCleveland$138
- Robert ZeeLancaster$137
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.